Our study, based on a real-world cohort of 288 stage IV patients treated and evaluated in a single institution, provides new insights into the prognostic and predictive role of KRAS mutations in advanced ns-NSCLC, particularly in the context of immunotherapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.